Document Detail


Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
MedLine Citation:
PMID:  8564129     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We tested the hypothesis that recombinant human deoxyribonuclease 1 (rhDNase) reduces airflow obstruction and improves mucociliary clearance in patients with cystic fibrosis (CF), and that improvements seen in FEV1 and FVC after rhDNase treatment are independent of chest physical therapy (CPT). CF patients inhaled placebo (10 patients) or 2.5 mg rhDNAse aerosol (10 patients) twice a day for six consecutive days. Compared with baseline, there were no statistically significant differences between the two study groups by Day 6 for indices of airflow obstruction obtained from gamma-camera images of the right lung following inhalation of 99mTc aerosol, or for mucociliary clearance or the rate of clearance of the radioaerosol, quantified over a 6-h period. By Day 6, FEV1 and FVC were significantly higher in the rhDNase-treated group than in the placebo group, increasing by an average of 9.4 +/- 3.5% and 12.7 +/- 2.6%, respectively, as compared with a decrease of 1.8 +/- 1.7% and an increase of 0.4 +/- 1.1%, respectively (p < 0.05). There was no significant change in the FEV1/FVC ratio on Day 6 (0.68 +/- 0.05) compared with baseline (0.70 +/- 0.05) in the rhDNase group. On Day 6, FEV1 and FVC decreased after CPT in both study groups, but the decreases were not significant. Our results indicate that aerosolized rhDNase improves FEV1 and FVC independent of CPT. We were unable to demonstrate that rhDNase reduces airflow obstruction or improves mucociliary clearance.
Authors:
B L Laube; R M Auci; D E Shields; D H Christiansen; M K Lucas; H J Fuchs; B J Rosenstein
Related Documents :
2866059 - Circulating histamine and neutrophil chemotactic activity during allergen-induced asthm...
3792079 - Bronchial reactivity increases soon after the immediate response in dual-responding ast...
15696079 - Leukotriene e(4)-induced persistent eosinophilia and airway obstruction are reversed by...
10808169 - Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acu...
8751019 - Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor m...
12654629 - Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of...
23959319 - Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis:...
8584649 - Selectivity of mdl 72,974a for mao-b inhibition based on substrate and metabolite conce...
3565909 - Comparison of various treatments for experimentally induced equine infectious arthritis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  153     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-03-06     Completed Date:  1996-03-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  752-60     Citation Subset:  AIM; IM    
Affiliation:
Department of Environmental Health Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adolescent
Adult
Aerosols
Cystic Fibrosis / drug therapy,  metabolism,  physiopathology*,  therapy
Deoxyribonuclease I / administration & dosage,  pharmacokinetics,  therapeutic use*
Double-Blind Method
Expectorants / administration & dosage,  pharmacokinetics,  pharmacology*
Female
Forced Expiratory Volume / drug effects
Humans
Lung / metabolism
Male
Mucociliary Clearance / drug effects*
Particle Size
Pulmonary Ventilation / drug effects*
Recombinant Proteins / administration & dosage,  pharmacokinetics,  therapeutic use
Respiratory Therapy
Vital Capacity / drug effects
Chemical
Reg. No./Substance:
0/Aerosols; 0/Expectorants; 0/Recombinant Proteins; EC 3.1.21.1/DNASE1 protein, human; EC 3.1.21.1/Deoxyribonuclease I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of inhaled nitric oxide in pediatric asthma.
Next Document:  Ventilatory responses to passive leg motion in children with congenital central hypoventilation synd...